Arrowhead Pharmaceuticals Seeks Shareholder Approval for Significant Equity Incentive Plan Expansion
ARWR has more than doubled off its 52-week low of $9.57.
Summary
Arrowhead Pharmaceuticals filed its definitive proxy statement, seeking shareholder approval for a significant expansion of its equity incentive plan by 10.5 million shares, representing approximately 7.5% potential dilution. The filing also discloses that the CEO has pledged shares valued at about $79.5 million.
Key Events · Corporate Governance and Compliance · ARWR
-
Proposed Equity Incentive Plan Expansion
The company is seeking approval to increase the shares available for its 2021 Incentive Plan by 10,500,000, which would result in approximately 7.5% potential dilution and raise the equity overhang from 5.6% to 11.8%.
-
CEO Share Pledge Disclosure
CEO Christopher Anzalone has pledged 1,192,897 shares, valued at approximately $79.5 million, as collateral for a line of credit, representing about 0.87% of the company's market capitalization.
-
Director Retirement
Director Douglas Ingram is not standing for re-election and will retire from the Board, reducing the board size to seven directors.
-
Related-Party Transactions Disclosed
The filing details consulting fees of $280,000 for Dr. Bruce Given, brother of a former director, and compensation for Vincent Anzalone, brother of the CEO, as Senior Vice President.
Analysis · ARWR · Life Sciences
Arrowhead Pharmaceuticals is seeking shareholder approval for its Amended and Restated 2021 Incentive Plan, which proposes to increase the total number of shares available for stock-based awards by 10,500,000. This represents a potential dilution of approximately 7.5% of the current outstanding shares and would increase the company's overhang from 5.6% to 11.8%. While framed as essential for attracting and retaining talent, this substantial increase in potential dilution could be viewed negatively by existing shareholders, especially following the company's recent capital raises totaling $930 million. Additionally, the CEO, Christopher Anzalone, has pledged 1,192,897 shares, valued at approximately $79.5 million, as collateral for a line of credit. This pledge, representing about 0.87% of the company's market capitalization, is a notable personal financial transaction that could signal liquidity needs or a potential future sale, adding a layer of concern for investors.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARWR was trading at $66.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1B. The 52-week trading range was $9.57 to $76.76. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.